Market Pulse Archives

Dec. 22, 2006, 11:00 a.m. EST

Oncolytics starts patient enrollment in Reolysin trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Oncolytics Biotech Inc. (ONCY)
  • X
    Oncolytics Biotech Inc. (ONC)

or Cancel Already have a watchlist? Log In

By Gabriel Madway

SAN FRANCISCO (MarketWatch) -- Oncolytics Biotech Inc. /zigman2/quotes/204741333/composite ONCY +0.0078% /zigman2/quotes/203812837/delayed CA:ONC 0.00% said Friday it has begun patient enrolment in its U.K. Phase II clinical trial to evaluate the anti-tumor effects of Reolysin in combination with low-dose radiation in patients with advanced cancers. Shares of Calgary, Alberta-based Oncolytics rose 12% to $2.02 in Friday morning trade.

/zigman2/quotes/204741333/composite
US : U.S.: Nasdaq
$ 1.28
+0.0001 +0.0078%
Volume: 33,154
Aug. 10, 2022 11:15a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$74.75 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/203812837/delayed
CA : Canada: Toronto
$ 1.67
0.00 0.00%
Volume: 7,328
Aug. 10, 2022 10:49a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$96.25 million
Rev. per Employee
N/A
loading...

Get news alerts on Oncolytics Biotech Inc. — or create your own.
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.